Ip ptx

Phase 2

MM.D. Anderson Cancer Center

Ip ptx is one of 6 therapeutic programs targeting Ivonescimab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

IvonescimabNot yet recruiting

IvonescimabPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Ivonescimab

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 2

3 2

Vepesid

AAvyxa

Phase 2

1 3

Carboplatin AUC-5

Merck & Co.

Phase 2

1 4

AK117

AAkeso

Phase 2

1 5

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

1 6

Ip ptx

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Not yet recruiting

Ivonescimab

NCT07753824

Clinical

Trials by Indication[1]

Ivonescimab1 trial

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07753824·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ip ptx. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ip ptx. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Ip ptx

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Ivonescimab1 trial

References

Drug Info

Quick Facts

Related News